



Angiogenesis and Anti-angiogenic Therapies

Guest Editor:

Dr. Madhuri Wadehra

Department of Pathology and
Lab Medicine, DGSOM at UCLA,
Los Angeles, USA

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editor

As Judah Folkman proposed 40 years ago, the sprouting of new vessels out of existing ones was considered as an exclusive way of tumor vascularisation. In neoplastic tissue, this process is multidimensionally regulated by tumor cells and a variety of stromal cells. While many growth factors and mechanisms have been unraveled, new complexities are constantly being discovered, such as with the recruitment of endothelial progenitor cells, vessel co-option, vasculogenic mimicry, and lymphangiogenesis to tumor growth, to name a few. Nonetheless, targeting tumor angiogenesis is a fast-growing domain in cancer therapeutics. Although anti-tumor targeting strategies have proven to be more complex than initially thought, several anti-angiogenics have proven successful for select tumor types.

In this *Cancers* review, we seek to obtain high-quality reviews on various aspects of the mechanism of tumor neoangiogenesis as well as successes and failures associated with anti-angiogenetics. Each review may focus broadly on the processes associated with tumor angiogenesis or take a more focused approach to discuss processes unique to a particular tumor type.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI